Bortezomib relieves immune tolerance in nasopharyngeal carcinoma via STAT1 suppression and indoleamine 2,3-dioxygenase downregulation

Cancer Immunology Research

Volumn 5, Issue 1, 2017, Pages 42-51

  Jiang, Guan Min ^a   Wang, Hong Sheng ^b   Du, Jun ^b   Ma, Wei Feng ^c   Wang, Hui ^d   Qiu, Yu ^e   Zhang, Qiu Gui ^f   Xu, Wei ^f   Liu, Hui Fang ^f   Liang, Jian Ping ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d Key Laboratory of Translational Radiation Oncology   (China)

^e HUNAN CHILDREN'S HOSPITAL   (China)

^f THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GAMMA INTERFERON; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON REGULATORY FACTOR 1; STAT1 PROTEIN; ANTINEOPLASTIC AGENT; PROTEIN BINDING;

ARTICLE; BIOLOGICAL ACTIVITY; CARCINOMA CELL LINE; CNE1 CELL LINE; CNE2 CELL LINE; CONTROLLED STUDY; CYTOPLASM; DEGRADATION; DRUG CYTOTOXICITY; GENE REPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; NASOPHARYNX CARCINOMA; NEGATIVE FEEDBACK; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; TRANSCRIPTION INITIATION; UBIQUITINATION; CARCINOMA; CELL SURVIVAL; DRUG EFFECTS; ENZYME ACTIVATION; IMMUNOLOGY; METABOLISM; NASOPHARYNX TUMOR; NUCLEOCYTOPLASMIC TRANSPORT; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; BORTEZOMIB; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; NASOPHARYNGEAL NEOPLASMS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN BINDING; STAT1 TRANSCRIPTION FACTOR;

EID: 85016122182     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-16-0102     Document Type: Article

References (37)

1. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, et al. Nasopharyngeal carcinomas: An update. Eur J Cancer 2003;39: 2121-35.
2. Liu P, Xie BL, Cai SH, He YW, Zhang G, Yi YM, et al. Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes. BMC Cancer 2009; 9:416.
3. Chan AT. Nasopharyngeal carcinoma. Ann Oncol 2010;21(Suppl 7): vii308-312.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
5. Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014;10:3111-6.
6. Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, et al. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009;113:2442-50.
7. Luo C, Wang JJ, Li YH, Hu JY, Li GC. Immunogenicity and efficacy of aDNA vaccine encoding a human anti-idiotype single chain antibody against nasopharyngeal carcinoma. Vaccine 2010;28:2769-74.
8. Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: New approaches to an old challenge. Cancer Res 2015;75:5-10.
9. Jiang GM, Xie WY, Wang HS, Du J, Wu BP, Xu W, et al. Curcumin combined with FAPalphac vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-alpha in melanoma. Oncotarget 2015;6:25932-42.
10. Williams CA, Harry RA, McLeod JD. Apoptotic cells induce dendritic cellmediated suppression via interferon-gamma-induced IDO. Immunology 2008;124:89-101.
11. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9: 1269-74.
12. Jiang GM, He YW, Fang R, Zhang G, Zeng J, Yi YM, et al. Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels. Int J Biochem Cell Biol 2010;42:1840-6.
13. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-54.
14. Ben-Haj-Ayed A, Moussa A, Ghedira R, Gabbouj S, Miled S, Bouzid N, et al. Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma. Immunol Lett 2016;169:23-32.
15. Grohmann U, Fallarino F, Puccetti P. Tolerance, DCs and tryptophan: Much ado about IDO. Trends Immunol 2003;24:242-8.
16. He YW, Wang HS, Zeng J, Fang X, Chen HY, Du J, et al. Sodium butyrate inhibits interferon-gamma induced indoleamine 2,3-dioxygenase expression via STAT1 in nasopharyngeal carcinoma cells. Life Sci 2013; 93:509-15.
17. Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010;115:3520-30.
18. Koblish HK, Hansbury MJ, Bowman KJ, Yang G, Neilan CL, Haley PJ, et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010; 9:489-98.
19. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, et al. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 2014; 20:221-32.
20. Vacchelli E, Aranda F, Eggermont A, Sautes-Fridman C, Tartour E, Kennedy EP, et al. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology 2014;3:e957994.
21. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
22. Cusack JC. Rationale for the treatment of solid tumorswith the proteasome inhibitor bortezomib. Cancer Treat Rev 2003;29Suppl 1:21-31.
23. Hui KF, Lam BH, Ho DN, Tsao SW, Chiang AK. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus. Mol Cancer Ther 2013;12:747-58.
24. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, et al. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 2006;176:4757-65.
25. Yan M, Zhang Y, He B, Xiang J, Wang ZF, Zheng FM, et al. IKKalpha restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation. Nat Commun 2014;5:3661.
26. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-86.
27. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
28. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gammainducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996;271:17247-52.
29. Dai W, Gupta SL. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J Biol Chem 1990;265:19871-7.
30. Kadoya A, Tone S, Maeda H, Minatogawa Y, Kido R. Gene structure of human indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun 1992;189:530-6.
31. Robinson CM, Hale PT, Carlin JM. The role of IFNgamma and TNF-alpharesponsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interferon Cytokine Res 2005;25:20-30.
32. Chon SY, Hassanain HH, Pine R, Gupta SL. Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2,3-dioxygenase gene. J Interferon Cytokine Res 1995;15:517-26.
33. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int 2005;5:18.
34. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS- 341 for the treatment of cancer. Curr Opin Chem Biol 2002;6:493-500.
35. Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 2014;28:258-68.
36. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets 2011;11:239-53.
37. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factorkappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7:1419-28.